Trial Profile
PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms PERFECT
- 08 Jun 2021 Results of circulating tumor analysis to predict pathological complete response and recurrence by using data from this study presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 06 Apr 2021 Results assessing the feasibility and preliminary efficacy of 40 patients treated with neoadjuvant chemoradiotherapy (nCRT) with programmed-death ligand-1 (PD-L1) immune checkpoint inhibition (ICI) using atezolizumab for resectable locally advanced esophagus and gastroesophageal junction adenocarcinoma published in the Clinical Cancer Research
- 27 Jan 2021 Results assessing safety and efficacy of atezolizumab combined with neoadjuvant chemoradiotherapy in patients with resectable esophageal adenocarcinoma published in the Clinical Cancer Research